Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/23/2026 | Equal Weight → Overweight | Barclays | ||
| 9/16/2025 | Overweight → Equal Weight | Barclays | ||
| 9/10/2025 | Neutral → Buy | Goldman | ||
| 6/5/2025 | $16.89 | Hold → Buy | HSBC Securities | |
| 5/27/2025 | $13.40 | Neutral → Outperform | BNP Paribas Exane | |
| 5/9/2025 | $11.25 | Equal-Weight → Overweight | Morgan Stanley | |
| 3/5/2025 | Buy → Hold | HSBC Securities | ||
| 1/10/2025 | Overweight → Equal-Weight | Morgan Stanley |
3 - DR REDDYS LABORATORIES LTD (0001135951) (Issuer)
3 - DR REDDYS LABORATORIES LTD (0001135951) (Issuer)
3 - DR REDDYS LABORATORIES LTD (0001135951) (Issuer)
From the gum expert brand, the new daily toothpaste and mouthwash help strengthen and protect gums, supporting healthy gum hydration, while featuring hyaluronic acid for enhanced foaming and freshness. Key Takeaways: parodontax expands its gum care portfolio with NEW Gum Strengthen & Protect Toothpaste and Mouthwash with Hyaluronic Acid^ Gum Strengthen & Protect is formulated to: Strengthen the gum seal for long-lasting gum protection with continued twice daily use Kill plaque bacteria along the gumline to support a stronger, tighter seal between gums and teeth with continued twice daily use Support healthy gum hydration Enhanced with Hyaluronic Acid^ as part of everyd
£65m investment in new oral health manufacturing plant in Shanghai to support growth in the world's largest gum health market Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 - including its fastest growing cities – reaching aspirational shoppers in-store and online Custom designed taste, foamier sensation and premium packaging to appeal to local consumers Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and p
An analysis of the COSMOS randomized trial provides early evidence that taking a daily multivitamin may help support healthy aging at the cellular level A new ancillary study published in Nature Medicine shows that Centrum Silver may slow biological aging markers. The findings come from an analysis of data from a randomized clinical trial, the COcoa Supplement and Multivitamin Outcomes Study (COSMOS), designed to evaluate how daily multivitamin use may influence biological aging over time. Biological aging refers to how well the body is functioning at a cellular level and may add important information about health span than chronological age alone. Led by researchers at Mass General Bri
Barclays upgraded Haleon plc from Equal Weight to Overweight
Barclays downgraded Haleon plc from Overweight to Equal Weight
Goldman upgraded Haleon plc from Neutral to Buy
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
LONDON, June 24, 2025 /PRNewswire/ -- Haleon (LSE: HLN) (NYSE:HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025. This appointment follows Franck Riot deciding to leave Haleon after six years in the business. Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care. Brian McNamara, Haleon's Chief Executive Officer commented: "I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experi
SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ) for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and
WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- Haleon, a world-leading consumer health company, is pleased to announce the appointment of Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024. In this role, Joe will lead the organization's customer strategy, driving growth and transformation in the US market. Joe brings extensive leadership experience to the role, having spent over 20 years in the FMCG sector and serving in the military. Most recently Joe led Unilever's Walmart business, overseeing the company's largest US customer. In his
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q1 FY26 Revenues ₹ 85,452 Mn [Up: 11% YoY; Flat QoQ] Gross Margin 56.9% [Q1FY25: 60.4%; Q4FY25: 55.6%] SG&A Expenses ₹ 25,647 Mn [Up: 13% YoY; 7% QoQ] R&D Expenses ₹ 6,244 Mn [7.3% of Revenues] EBITDA ₹ 22,784 Mn [26.7% of Revenues] Profit before
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25 Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^] Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%] SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY] R&D Expens
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY25 9MFY25 Revenues ₹ 83,586 Mn ₹ 240,475 Mn [Up: 16% YoY^; 4% QoQ] [Up: 15% YoY^] Gross Margin 58.7% 59.5% [Q3FY24: 58.5%; Q2FY25: 59.6%] [9MFY24: 58.6%] SG&A Expenses ₹ 24,117 Mn ₹ 69,815 Mn [Up: 19% YoY; 5% QoQ] [Up: 23% YoY] R&D Expenses ₹ 6,658 Mn ₹ 20,122 Mn [8.0% o
SC 13G - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)